HomeCompareCPHRF vs VYM

CPHRF vs VYM: Dividend Comparison 2026

CPHRF yields 15.38% · VYM yields 2.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CPHRF wins by $26.9K in total portfolio value
10 years
CPHRF
CPHRF
● Live price
15.38%
Share price
$13.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54.8K
Annual income
$3,973.98
Full CPHRF calculator →
VYM
Vanguard High Dividend Yield ETF
● Live price
2.41%
Share price
$145.48
Annual div
$3.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$278.55
Full VYM calculator →

Portfolio growth — CPHRF vs VYM

📍 CPHRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCPHRFVYM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CPHRF + VYM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CPHRF pays
VYM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CPHRF
Annual income on $10K today (after 15% tax)
$1,307.69/yr
After 10yr DRIP, annual income (after tax)
$3,377.88/yr
VYM
Annual income on $10K today (after 15% tax)
$205.23/yr
After 10yr DRIP, annual income (after tax)
$236.77/yr
At 15% tax rate, CPHRF beats the other by $3,141.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CPHRF + VYM for your $10,000?

CPHRF: 50%VYM: 50%
100% VYM50/50100% CPHRF
Portfolio after 10yr
$41.3K
Annual income
$2,126.26/yr
Blended yield
5.15%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CPHRF buys
0
VYM buys
1
PoliticianChamberTickerTypeAmountDate
Carol Devine Miller🏢 House$VYM▲ Buy$15,001 - $50,0002022-11-02
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCPHRFVYM
Forward yield15.38%2.41%
Annual dividend / share$2.00$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$54.8K$27.8K
Annual income after 10y$3,973.98$278.55
Total dividends collected$26.9K$2.6K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CPHRF vs VYM ($10,000, DRIP)

YearCPHRF PortfolioCPHRF Income/yrVYM PortfolioVYM Income/yrGap
1← crossover$12,238$1,538.46$11,151$241.44+$1.1KCPHRF
2$14,855$1,759.66$12,413$246.79+$2.4KCPHRF
3$17,891$1,996.12$13,794$251.79+$4.1KCPHRF
4$21,390$2,246.80$15,306$256.47+$6.1KCPHRF
5$25,398$2,510.50$16,960$260.84+$8.4KCPHRF
6$29,961$2,785.88$18,768$264.92+$11.2KCPHRF
7$35,130$3,071.47$20,745$268.71+$14.4KCPHRF
8$40,955$3,365.74$22,905$272.24+$18.1KCPHRF
9$47,489$3,667.11$25,265$275.51+$22.2KCPHRF
10$54,787$3,973.98$27,842$278.55+$26.9KCPHRF

CPHRF vs VYM: Complete Analysis 2026

CPHRFStock

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.

Full CPHRF Calculator →

VYMETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →
📬

Get this CPHRF vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CPHRF vs SCHDCPHRF vs JEPICPHRF vs OCPHRF vs KOCPHRF vs MAINCPHRF vs VIGCPHRF vs DGROCPHRF vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.